Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting

Posted on AllSides December 10th, 2019
From The Center

A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of experimental therapies that would grow those markets is exciting investors.

This week, much of the high-profile clinical data coming out of the American Society of Hematology’s annual meeting in Orlando, Fla., focused on companies developing products that aim to fit the needs of these patients.

Read full story
https://www.marketwatch.com/story/investors-shift-attention-to-next-generation-of-car-t-new-sickle-cell-treatments-at-major-hematology-meeting-2019-12-10

More News about Science from the Left, Center and Right

From the Left

From the Center

From the Right